About Envoy Therapeutics, Inc.
Started with an initial $8 million financing in October 2009, Envoy Therapeutics used a proprietary technology called bacTRAP to identify target proteins expressed in the circuitry of neurological and psychiatric diseases and then discovered and optimized drug compounds that acted on those proteins. In November 2012, Takeda Pharmaceuticals purchased Envoy for $140 million.
Envoy Therapeutics, Inc. Job Openings
Create job profile to receive interview calls for your dream job
Create Job Alert Kick Start! your career with best matching jobs
Location
X